β-Carotene Supplementation and Lung Cancer Incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: The Role of Tar and Nicotine.
Aged
Antioxidants
/ administration & dosage
Dietary Supplements
/ adverse effects
Double-Blind Method
Finland
/ epidemiology
Follow-Up Studies
Humans
Incidence
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Nicotine
/ analysis
Provitamins
/ adverse effects
Smoking
/ adverse effects
Tars
/ analysis
alpha-Tocopherol
/ administration & dosage
beta Carotene
/ administration & dosage
Journal
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751
Informations de publication
Date de publication:
17 07 2019
17 07 2019
Historique:
received:
16
10
2017
accepted:
04
06
2018
pubmed:
12
6
2018
medline:
15
4
2020
entrez:
12
6
2018
Statut:
ppublish
Résumé
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study demonstrated that β-carotene supplementation increases lung cancer incidence in smokers. Further, cigarettes with higher tar and nicotine content are associated with a higher risk of lung cancer. However, no studies have examined whether the increased risk associated with β-carotene supplementation in smokers varies by the tar or nicotine content of cigarettes. The ATBC Study was a randomized, double-blind intervention trial conducted in southwest Finland. A total of 29 133 male smokers, aged 50-69 years, were enrolled and randomly assigned to one of four groups (α-tocopherol, β-carotene, both, or placebo). Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) of lung cancer risk by β-carotene trial assignment stratified by a priori categories of cigarette tar and nicotine content. The β-carotene supplementation group had significantly higher risk of developing lung cancer in all categories of tar content (yes vs. no β-carotene supplementation-ultralight cigarettes [≤7 mg tar]: HR = 1.31, 95% CI = 0.91 to 1.89; nonfiltered cigarettes [≥21 mg tar]: HR = 1.22, 95% CI = 0.91 to 1.64; p for interaction = .91). Similarly, there was no interaction with nicotine content (yes vs. no β-carotene supplementation-ventilated cigarettes [≤0.8 µg nicotine]: HR = 1.23, 95% CI = 0.98 to 1.54; nonfiltered cigarettes [≥1.3 µg nicotine]: HR = 1.22, 95% CI = 0.91 to 1.64; p for interaction = .83). These findings support the conclusion that supplementation with β-carotene increases the risk of lung cancer in smokers regardless of the tar or nicotine content of cigarettes smoked. Our data suggest that all smokers should continue to avoid β-carotene supplementation. Previous studies demonstrated that β-carotene supplementation increases risk of lung cancer in smokers. This study moves the field forward by examining the potential for modification of risk of lung cancer with different levels of tar and nicotine in cigarettes smoked, as interaction with carcinogens in these components of cigarette smoke is hypothesized to be the mechanism by which β-carotene increases risk. Our study provides evidence that the increased risk of lung cancer in smokers who take β-carotene supplements is not dependent upon the tar or nicotine level of cigarettes smoked and suggests that all smokers should continue to avoid β-carotene supplementation.
Identifiants
pubmed: 29889248
pii: 5034687
doi: 10.1093/ntr/nty115
pmc: PMC6636175
doi:
Substances chimiques
Antioxidants
0
Provitamins
0
Tars
0
tobacco tar
0
beta Carotene
01YAE03M7J
Nicotine
6M3C89ZY6R
alpha-Tocopherol
H4N855PNZ1
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1045-1050Informations de copyright
Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco 2018.
Références
BMJ. 2004 Jan 10;328(7431):72
pubmed: 14715602
Nat Rev Cancer. 2014 Jun;14(6):419-29
pubmed: 24827506
J Carcinog. 2013 Jan 31;12:1
pubmed: 23599683
Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1376-83
pubmed: 15941944
Nutr Cancer. 2009;61(6):767-74
pubmed: 20155614
J Natl Cancer Inst. 1996 Nov 6;88(21):1560-70
pubmed: 8901854
J Natl Cancer Inst. 1999 Jan 6;91(1):60-6
pubmed: 9890171
Clin Chest Med. 2011 Dec;32(4):605-44
pubmed: 22054876
Am Rev Respir Dis. 1982 Aug;126(2):258-64
pubmed: 7103252
PLoS One. 2009 Oct 20;4(10):e7524
pubmed: 19841737
N Engl J Med. 1994 Apr 14;330(15):1029-35
pubmed: 8127329
BMJ. 1993 Jun 12;306(6892):1567-70
pubmed: 8329914
JAMA. 2003 Jul 23;290(4):476-85
pubmed: 12876090
Nicotine Tob Res. 2009 Jan;11(1):12-24
pubmed: 19246437
Am J Clin Nutr. 1995 Dec;62(6 Suppl):1427S-1430S
pubmed: 7495243
Br Med J. 1980 Apr 5;280(6219):972-6
pubmed: 7417765
Acta Oncol. 2002;41(4):381-8
pubmed: 12234031
Environ Res. 1976 Dec;12(3):263-74
pubmed: 1001298
Am J Epidemiol. 1989 Apr;129(4):703-11
pubmed: 2923118
J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210
pubmed: 10413421
Prev Med. 1989 Jul;18(4):518-25
pubmed: 2798373
Cancer Causes Control. 1991 Sep;2(5):325-57
pubmed: 1834240
Ann Epidemiol. 1994 Jan;4(1):1-10
pubmed: 8205268
Prev Med. 1988 May;17(3):263-72
pubmed: 3405983
BMC Cancer. 2015 Mar 19;15:152
pubmed: 25885699
Cancer Causes Control. 1991 Nov;2(6):427-42
pubmed: 1764568
J Natl Cancer Inst. 1996 Nov 6;88(21):1550-9
pubmed: 8901853
Am J Clin Nutr. 1999 Jun;69(6):1345S-1350S
pubmed: 10359235